As anticipated, these molecules do not dramatically affect the DLBCL cellular viability; thus, minor substitution to our selected compounds that hampers their eIF4A inhibitory capacity also displays a minor reduction in potency of DLBCL cellular viability. The gene discussed is EIF4A2; the disease is diffuse large B-cell lymphoma.